[1]
Gao M, Zhang W, Zhao W, Qin L, Pei F, Zheng Y. Loeffler endocarditis as a rare cause of heart failure with preserved ejection fraction: A case report and review of literature. Medicine. 2018 Mar:97(11):e0079. doi: 10.1097/MD.0000000000010079. Epub
[PubMed PMID: 29538200]
Level 2 (mid-level) evidence
[2]
Dregoesc MI, Iancu AC, Lazar AA, Balanescu S. Hypereosinophilic syndrome with cardiac involvement in a patient with multiple malignancies. Medical ultrasonography. 2018 Aug 30:20(3):399-400. doi: 10.11152/mu-1574. Epub
[PubMed PMID: 30167597]
[3]
Allderdice C, Marcu C, Kabirdas D. Intracardiac Thrombus in Leukemia: Role of Cardiac Magnetic Resonance Imaging in Eosinophilic Myocarditis. CASE (Philadelphia, Pa.). 2018 Jun:2(3):114-117. doi: 10.1016/j.case.2017.12.003. Epub 2018 Apr 14
[PubMed PMID: 30062326]
Level 3 (low-level) evidence
[4]
Jin X, Ma C, Liu S, Guan Z, Wang Y, Yang J. Cardiac involvements in hypereosinophilia-associated syndrome: Case reports and a little review of the literature. Echocardiography (Mount Kisco, N.Y.). 2017 Aug:34(8):1242-1246. doi: 10.1111/echo.13573. Epub 2017 Jun 1
[PubMed PMID: 28573678]
Level 3 (low-level) evidence
[5]
Doyen D, Buscot M, Eker A, Dellamonica J. Endomyocardial fibrosis complicating primary hypereosinophilic syndrome. Intensive care medicine. 2018 Dec:44(12):2294-2295. doi: 10.1007/s00134-018-5300-z. Epub 2018 Jul 13
[PubMed PMID: 30006894]
[6]
Boggild AK, Keystone JS, Kain KC. Tropical pulmonary eosinophilia: a case series in a setting of nonendemicity. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2004 Oct 15:39(8):1123-8
[PubMed PMID: 15486834]
Level 2 (mid-level) evidence
[7]
Nanagas VC,Kovalszki A, Gastrointestinal Manifestations of Hypereosinophilic Syndromes and Mast Cell Disorders: a Comprehensive Review. Clinical reviews in allergy & immunology. 2018 Jul 12
[PubMed PMID: 30003499]
[8]
Hayashi S, Isobe M, Okubo Y, Suzuki J, Yazaki Y, Sekiguchi M. Improvement of eosinophilic heart disease after steroid therapy: successful demonstration by endomyocardial biopsied specimens. Heart and vessels. 1999:14(2):104-8
[PubMed PMID: 10651187]
[9]
Gottdiener JS, Maron BJ, Schooley RT, Harley JB, Roberts WC, Fauci AS. Two-dimensional echocardiographic assessment of the idiopathic hypereosinophilic syndrome. Anatomic basis of mitral regurgitation and peripheral embolization. Circulation. 1983 Mar:67(3):572-8
[PubMed PMID: 6821899]
[10]
Alam A, Thampi S, Saba SG, Jermyn R. Loeffler Endocarditis: A Unique Presentation of Right-Sided Heart Failure Due to Eosinophil-Induced Endomyocardial Fibrosis. Clinical medicine insights. Case reports. 2017:10():1179547617723643. doi: 10.1177/1179547617723643. Epub 2017 Aug 30
[PubMed PMID: 28890659]
Level 3 (low-level) evidence
[11]
Hernandez CM, Arisha MJ, Ahmad A, Oates E, Nanda NC, Nanda A, Wasan A, Caleti BE, Bernal CLP, Gallardo SM. Usefulness of three-dimensional echocardiography in the assessment of valvular involvement in Loeffler endocarditis. Echocardiography (Mount Kisco, N.Y.). 2017 Jul:34(7):1050-1056. doi: 10.1111/echo.13575. Epub 2017 Jun 9
[PubMed PMID: 28600838]
[12]
Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunology and allergy clinics of North America. 2007 Aug:27(3):457-75
[PubMed PMID: 17868859]
[13]
Chen YW, Chang YC, Su CS, Chang WC, Lee WL, Lai CH. Dramatic and early response to low-dose steroid in the treatment of acute eosinophilic myocarditis: a case report. BMC cardiovascular disorders. 2017 May 8:17(1):115. doi: 10.1186/s12872-017-0547-9. Epub 2017 May 8
[PubMed PMID: 28482853]
Level 3 (low-level) evidence
[15]
Pitini V, Arrigo C, Azzarello D, La Gattuta G, Amata C, Righi M, Coglitore S. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood. 2003 Nov 1:102(9):3456-7; author reply 3457
[PubMed PMID: 14568908]
[16]
Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood. 2006 Jan 15:107(2):558-65
[PubMed PMID: 16166591]